

Wara Samar
24th January 2025
Lindus Health Secures $55 Million to Transform Clinical Trials with AI
Lindus Health, a four-year-old disruptor in the clinical trials space, has announced a successful $55 million Series B funding round. The company, which emerged as the winner of the 2024 MedTech World Startup Pitch Competition in London, is positioning itself as a transformative force in an industry traditionally dominated by contract research organizations (CROs).
Leveraging artificial intelligence, Lindus Health aims to address inefficiencies in the clinical trial process, a critical step in bringing new medicines and medical devices to market. The company’s platform provides end-to-end solutions for running trials, integrating automation to reduce time and labor-intensive tasks. By branding itself as the “anti-CRO,” Lindus Health underscores its departure from conventional approaches that often rely heavily on external organizations.
The Need for Change in Clinical Trials
The clinical trials industry, valued at $82 billion in 2023 and projected to grow to $130 billion by 2030, is often criticized for its complexity and lengthy timelines. From protocol design to patient recruitment and data collection, the traditional process can span years, delaying the availability of potentially life-saving treatments. Lindus Health’s AI-driven tools streamline these stages, accelerating timelines and reducing costs.
One key innovation is Lindus Health’s protocol generation tool, which uses machine learning trained on historical data to draft detailed trial plans. This approach minimizes the traditionally labor-intensive process, allowing faster regulatory submissions and trial launches. Beyond software, Lindus Health provides the necessary personnel for clinical trials, including medics, technologists, and regulatory experts.
Broadening the Scope of Clinical Trials
Since its establishment in 2021, Lindus Health has conducted trials across Europe and the U.S., addressing conditions such as asthma, diabetes, hypertension, weight management, and social anxiety. These complex and often neglected areas reflect the company’s commitment to tackling prevalent health issues. To date, Lindus Health has enrolled over 36,000 patients, emphasizing its capacity to deliver impactful clinical research.
Strategic Growth and Plans
With the new funding, Lindus Health plans to accelerate its global expansion, including relocating its global headquarters from the U.K. to the U.S. The company will also strengthen its commercial go-to-market team, explore more complex trial types, and enhance integrations with third-party systems like electronic medical records. Additionally, Lindus Health is investigating further AI applications to analyze trial data in real time, a move that could significantly advance decision-making in drug development.
Malcolm Fogarty, Advisor – Strategic Partnerships & Growth at Lindus Health, remarked, “Lindus empowers the development of novel medical devices every step of the way with our dynamic All-in-One Medical Device CRO solution. Our $55M Series B is a testament to the impact we are making for MedTech innovators and Lifescience pioneers, delivering fixed-price, end-to-end clinical trials that are up to three times faster and produce demonstrably better quality trial data than traditional players.”
The Series B round was led by Balderton Capital, with participation from Creandum, Firstminute, Seedcamp, and Visionaries Club. Combined with its previous $25 million in equity and grants, Lindus Health is well-positioned to impact the clinical trial industry.
As AI continues to revolutionize drug discovery and development, Lindus Health’s approach aligns with the growing demand for innovative solutions that bring treatments to market faster. By embracing automation and data-driven insights, the company is charting a path toward more efficient, inclusive, and impactful clinical trials.
Connect at MedTech World Dubai
Engage with MedTech innovators and leaders at MedTech World Dubai. Explore the latest breakthroughs, collaborate with industry professionals, and uncover new opportunities to drive progress in the healthcare ecosystem. Don’t miss this opportunity to be part of the ongoing advancements in medical technology. Book your ticket now!
